Wealthfront Advisers LLC Acquires New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Wealthfront Advisers LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 21,578 shares of the company’s stock, valued at approximately $592,000.

A number of other hedge funds also recently made changes to their positions in BBIO. State of New Jersey Common Pension Fund D lifted its holdings in shares of BridgeBio Pharma by 13.7% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 76,586 shares of the company’s stock valued at $1,950,000 after acquiring an additional 9,225 shares in the last quarter. Royce & Associates LP purchased a new stake in BridgeBio Pharma during the 3rd quarter worth $3,105,000. Mizuho Markets Americas LLC increased its stake in BridgeBio Pharma by 3.8% during the 3rd quarter. Mizuho Markets Americas LLC now owns 87,180 shares of the company’s stock worth $2,220,000 after buying an additional 3,198 shares during the period. Swiss National Bank increased its stake in BridgeBio Pharma by 1.1% during the 3rd quarter. Swiss National Bank now owns 219,300 shares of the company’s stock worth $5,583,000 after buying an additional 2,400 shares during the period. Finally, Quest Partners LLC increased its stake in BridgeBio Pharma by 134.0% during the 3rd quarter. Quest Partners LLC now owns 31,173 shares of the company’s stock worth $794,000 after buying an additional 17,849 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BBIO shares. Evercore ISI lifted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Citigroup boosted their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Finally, Bank of America boosted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $51.55.

Get Our Latest Research Report on BBIO

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 326,932 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now directly owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. The trade was a 5.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares of the company’s stock, valued at $634,841,604.16. The trade was a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,579,739 shares of company stock valued at $323,171,901 in the last ninety days. Company insiders own 24.66% of the company’s stock.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $32.97 on Monday. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The company has a 50-day simple moving average of $33.62 and a 200-day simple moving average of $28.88. The firm has a market capitalization of $6.27 billion, a PE ratio of -11.57 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million. Equities analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Featured Articles

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report).

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.